Jeremy D. Kark, MD, PhD; Jacob Selhub, PhD; Bella Adler, MA; Jaime Gofin, MD, MPH; Joseph H. Abramson, MB, BCh; Gideon Friedman, MD; Irwin H. Rosenberg, MD
Grant Support: In part by the U.S. Department of Agriculture, Agricultural Research Service (contract 53-3K06-5-10); by the Ridgefield Foundation (Ridgefield, Connecticut); and by the German Federal Ministry of Education and Research (BMBF) and the Israeli Ministry of Science under the aegis of the GSF- Forschungszentrum fuer Umwelt und Gesundheit GmbH, Neuherberg, Germany.
Requests for Reprints: Jeremy D. Kark, MD, PhD, Department of Social Medicine, Hadassah University Hospital, POB 12000, Ein Kerem 91120, Jerusalem; e-mail, firstname.lastname@example.org.
Current Author Addresses: Drs. Kark, Abramson, and Gofin and Ms. Adler: Department of Social Medicine, Hadassah University Hospital, POB 12000, Ein Kerem 91120, Jerusalem.
Drs. Selhub and Rosenberg: The Jean Mayer USDA Human Nutrition Center on Aging at Tufts University, 711 Washington Street, Boston, MA 02111.
Dr. Friedman: Geriatric Unit, Hadassah University Hospital, POB 12000, Ein Kerem 91120, Jerusalem.
Kark J., Selhub J., Adler B., Gofin J., Abramson J., Friedman G., Rosenberg I.; Nonfasting Plasma Total Homocysteine Level and Mortality in Middle-Aged and Elderly Men and Women in Jerusalem. Ann Intern Med. 1999;131:321-330. doi: 10.7326/0003-4819-131-5-199909070-00002
Download citation file:
Published: Ann Intern Med. 1999;131(5):321-330.
The metabolism of homocysteine, a sulfur amino acid, is at the intersection of two metabolic pathways: transsulfuration and remethylation (1). McCully (2) first proposed that severe hyperhomocysteinemia is related to both atherosclerosis and vascular thrombosis. Recent evidence (3-5) has shown an association between mildly to moderately elevated blood concentrations of total homocysteine and vascular disease (including its coronary, cerebral, and peripheral manifestations). Much of the supporting evidence for this association has been obtained from case–control studies; reports of prospective studies of cardiovascular disease, however, are inconsistent (6-12). It remains to be established whether this relation is causal and whether reduction of plasma homocysteine level will decrease risk. Most studies have been done in Europe and North America. Only two recent reports—one from the Framingham Study (13) and one on patients with coronary heart disease in Norway (14)—have used total mortality as an end point with which to assess health outcomes associated with a modestly elevated homocysteine level.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Cardiology, Endocrine and Metabolism, Geriatric Medicine, Diabetes, Coronary Risk Factors.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only